Loading
The first phase 3 win for ivonescimab, in lung cancer that has stopped responding to EGFR pills, and the basis of its first approval in China.
322 patients. Median progression-free survival 7.1 versus 4.8 months (hazard ratio 0.46) with benefit across subgroups including patients who had received third-generation EGFR inhibitors; published in JAMA in 2024. NMPA approval May 2024, the first for any PD-1 x VEGF bispecific antibody. Summit's global HARMONi trial in the same setting met progression-free survival but not overall survival at its 2025 analysis, the basis of a US filing with a November 2026 action date.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.
Shares Pemetrexed, Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.
Shares EGFR, Lung cancer (all types), Non-small-cell lung cancer and the tag china.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.